The ABRACL Knockout HEK293T Polyclonal Cells product comprises a population of HEK293T cells subjected to CRISPR/Cas9-mediated gene disruption targeting the human ABRACL locus. This polyclonal knockout cell pool enables loss-of-function analysis of ABRACL without the need for single-cell cloning, providing a heterogeneous representation of editing events. The cell population is designed for researchers requiring a robust ABRACL-deficient model in a widely used human embryonic kidney cell background.
The parental HEK293T cell line is a well-characterized human embryonic kidney epithelial cell line that stably expresses the SV40 large T antigen. These cells are commonly used for high-efficiency gene expression and protein production studies due to their high transfectability. Biologically, HEK293T cells derive from embryonic kidney tissue and retain features relevant to nephron progenitor function and kidney development, making them a suitable platform for examining gene functions associated with renal and cellular processes.
ABRACL encodes a protein that directly interacts with the CCR4-NOT deadenylase complex, a central regulator of mRNA poly(A) tail shortening and subsequent mRNA decay. Through its association with CNOT1 and CNOT7, core scaffolding and catalytic subunits of the CCR4-NOT complex, ABRACL influences the deadenylation and stability of target transcripts. This interaction positions ABRACL at the intersection of mRNA processing and cell proliferation control. Downstream effects on the PAN2-PAN3 complex and poly(A)-binding protein PABPC1 further integrate ABRACL into the mRNA degradation machinery. Consequently, ABRACL disruption may perturb mRNA homeostasis and cell cycle progression.
In the HEK293T background, ABRACL knockout provides a genetically defined system to delineate the protein??s role in coordinating mRNA metabolism with cellular growth. Given HEK293T cells?? origin from kidney epithelium, this model can offer insights into ABRACL??s function in developmental processes and oncogenic transformation. Aberrant ABRACL expression has been associated with hepatocellular carcinoma, breast cancer, and colorectal cancer, underscoring the clinical relevance of this knockout tool for cancer biology research.
Typical applications include mechanistic studies of mRNA deadenylation and decay by monitoring transcript stability, as well as cell proliferation assays (MTT, BrdU) to quantify ABRACL??s impact on growth. Co-immunoprecipitation experiments with CCR4-NOT components validate protein interactions, while RNA-sequencing enables transcriptome-wide analysis of expression changes upon ABRACL loss. This polyclonal knockout product is well-suited for high-throughput RNA processing screens. For further technical details, please contact Ascent Research.
